"Pharmaceutical Speed Reading Society" 2020 Health Insurance Directory announced that the Ipaval single anti-is to be included in the priority ...

December 28, 2020 / Medical Information List: 2020 National Health Insurance Directory Announced! Negotiated drug price reduction average 50.64 percent; Xinlitai: proposed transfer of two product-related interests; Vidicido single resistance approved by CDE breakthrough treatment; Ipaval single resistance in China to be included in the priority review; Cyntafal pearl monoantitone in China approved treatment of relapsed glioblastoma ... Daily fresh medicine news, speed reading society and you pay attention to! Part 1 Policy Brief 2020 National Health Care Directory Published! On December 28th, the State Administration of Health Insurance and the Ministry of Human Resources and Social Security published the National List of Medicines for Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance (2020), which will come into effect on March 1, 2021.
through this catalog adjustment, a total of 119 drugs were added to the catalog, and another 29 original drugs were transferred out of the catalog.
adjustment, the total number of medicines in the medical insurance catalogue is 2800, of which 1426 are Western medicine, 1374 are Chinese medicine, and the number of Chinese medicine tablets in the catalogue has not been adjusted, it is still 892.
119 new drugs, including 96 exclusive drugs negotiated and 23 non-exclusive drugs transferred directly, have a success rate of 73.46 percent.
prices for drugs negotiated in the united States have been reduced by an average of 50.64 per cent.
(National Health Insurance Administration) Amendments to the Criminal Law of the People's Republic of China (11) were adopted: On the afternoon of the 26th, the 24th session of the Standing Committee of the 13th National People's Congress voted to adopt the Amendments to the Criminal Law (11th), which will come into effect on March 1, 2021.
Amendments to the Criminal Law (11) add 13 new articles and amend 34 articles.
this revision mainly focuses on the criminal law governance and protection in the fields of safeguarding people's lives and safety, safe production, financial market order, intellectual property rights, ecological environment, public health and safety related to epidemic prevention and control.
(People's Congress Network) Part 2 production by observation Xinlitai: to transfer the rights and interests of two products 28, Xinlitai issued a notice that the company intends to sign an agreement with Blue Valley Pharmaceuticals, the transfer of all the company's hydrochloric acid erotinib, Devasalban products in the Chinese mainland rights and interests.
company will receive a total technology transfer fee of RMB84 million according to the progress of the agreement.
(Xinlitai Announcement) Fosun Pharma: Subsidiaries intend to participate in the establishment of the target fund Fosun Pharma Announcement, the company's holding subsidiary / enterprise Nanjing Fuxin, Ningbo Fuxuan and other four investors, including related parties Fosun Hi-Tech signed the "Target Fund Partnership Agreement", etc., to jointly fund the establishment of the target fund.
target fund will mainly invest in biomedicine, medical devices, biomass, precision therapy, in-body diagnosis, medical technology and other areas of equity participation projects.
fund plans to raise 1.5 billion yuan, of which the first round is to raise 1.0101 billion yuan.
(Fosun Pharma Announcement) Part 3 Pharmaceutical Information Vidicyto single resistance was approved by CDE breakthrough therapy on the 28th, Rongchang Bio-developed antibody conceding drug (ADC) Vidisitotin (disitamab vedotin, RC48-ADC) was officially awarded breakthrough therapy qualification by CDE.
are patients with localized late stage or metastatic urethra cancer (including bladder, urethra, kidney and urethra sources) who have progressed after failure of chemotherapy.
for the allergy, the FDA on September 21st granted Vidicido mono-breakthrough therapy approval.
(Medical Rubik's Cube) Ipaval monoantiton resistance in China to be included in the priority review! According to the latest publicity on the official website of CDE, the three emapalumab listing applications for Supi Pharmaceuticals are to be included in the priority review of "qualified approved drugs" for treatment in adults and children (newborns and above) with refractic, recurring or progressive diseases or insuperable to conventional HLH therapy for primary lymphocytosis (HLH) adults and children (newborns and above).
(Drug Mingkangde) micro-core bio-anti-tumor original innovative drug Theo Ronnie into the CDE "breakthrough treatment" micro-core biologics in the study of anti-tumor original innovative drug Chiauranib capsule was formally included in the CDE "breakthrough treatment drug varieties", into the adaptation market approval target confirmed phase III clinical trials for the treatment of patients with progression or recurrence of small cell lung cancer (SCLC) after the 2-line system chemotherapy program.
(US News Agency) Cyntafal bead monoantigen resistance in China was approved for the treatment of relapsed glioblastoma 28, Cyntaf announced its self-developed recombinant anti-VEGF humanized monoclonal antibody drug Dayo (Beval bead monoantigen, international trademark: Byvasda) officially obtained NMPA approval for the treatment of adult relapsed glioblastoma (GBM), which is the third adaptation approved by Davy.
was first approved for NMPA on June 17, 2020 for the treatment of advanced non-small cell lung cancer and metastatic colorectal cancer.
(Xinda Bio-announcement) People's Fu Pharmaceutical subsidiary Anli Shengtan tablets to obtain drug registration approval notice 28, People's Fu Pharmaceuticals subsidiary Wuhan People's Fu, the company holds 98.33 percent of its equity, holding subsidiary Yichang People's Fu Pharmaceutical Co., Ltd. holds 1.67 percent of its shares) recently received the State Drug Administration approved the issuance of Anlitan tablets of the "drug registration certificate."
(Sina Pharmaceutical News) Modern Pharmaceuticals: subsidiary 2 specifications of theacid saffentini injection to obtain a drug registration certificate modern pharmaceutical announcement, recently the company's wholly-owned subsidiary Guogong Limited received the Approval of the State Drug Administration issued the "sour scissine saffenite injection" 2 specifications of the drug registration certificate.
specifications: (1) 1 ml: 50 mg (by C22H30N2O2S) (2) 2 ml: 100 mg (by C22H30N2O2S).
(Modern Pharmaceutical Bulletin) East Sunshine: The subsidiary obtained the phosphate Emitaway capsule drug registration certificate East Sunshine announcement, the company's holding subsidiary Dongsian Pharmaceutical recently received the Approval of the State Drug Administration issued the "Drug Registration Certificate."
phosphate ethymethamivir is an oral direct anti-HCV drug, unstructic protein ("NS") 5A inhibitor.
(East Sunshine Announcement) Anti-HER2 dual-specific antibody KN026 and Aibo new joint drug treatment program approved clinical Corning Jerry Biopharmaceutical announced that the company has recently received the China National Drug Administration issued a drug clinical trial approval notice, approved to carry out K N026 combined with pyrethroids or KN026 in a joint with pyrithroids and fluvis groups for the treatment of her2-positive local late-stage non-excision and/or metastasis breast cancer that failed in the treatment of terpenes and yews.
(A.M.) Ganlai FXR agitator ASC42 completed the first phase I clinical trial in the United States subjects to the drug Ganlai Pharmaceuticals focused on the development and commercialization of innovative drugs in the field of non-alcoholic fatty hepatitis (NASH), is a wholly owned subsidiary of Goliath Pharmaceutical Co., Ltd. (HKEx Code: 1672).
announced today that its Farniol X-patient (FXR) astigtor, NASH candidate drug ASC42, has completed its first phase I clinical trial of the subject.
(Agency)